Molecularly Aided Stratification for Tumor Eradication Research

Launched by GERMAN CANCER RESEARCH CENTER · May 2, 2023

Keywords

ClinConnect Summary

The Molecularly Aided Stratification for Tumor Eradication Research trial is studying new ways to help patients with rare cancers receive better treatment. This research focuses on understanding the unique biological features of these cancers through advanced testing, which helps doctors make informed decisions about the best therapies for each individual patient. The study is actively recruiting participants who are adults aged 65 to 74 with rare cancers or rare subtypes of more common cancers. To be eligible, patients must have advanced cancer that cannot be cured and require systemic therapy, which means treatment that affects the whole body.

Participants in this trial can expect to undergo various molecular tests that will help identify the specific characteristics of their cancer. They will then be discussed in a special meeting called a multidisciplinary molecular tumor board, where doctors from different specialties will collaborate to plan the best treatment approach. It’s important to note that individuals with serious neurological or psychiatric disorders that could affect their ability to give consent will not be able to participate. Overall, this study aims to improve how we tailor cancer treatments for those facing these challenging diagnoses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Rare cancer (Incidence \<6/100,000 persons/year) or Rare subtype of a more common entity (case-by-case decision; example: pancreatic ductal adenocarcinoma without KRAS mutation)
• • Metastatic and/or locally advanced cancer with no curative therapy option and indication for systemic therapy
• Exclusion Criteria:
• • Severe neurological or psychiatric disorder interfering with the ability to give oral and written informed consent